Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

Completed · Phase 2 · Has a placebo group

Conditions studied: Sickle Cell Disease, Priapism

In brief

This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).

Key facts

Study ID

NCT00940901

Run by

Johns Hopkins University

People needed

13

Starts

2008-06-01

Expected to finish

2013-12-01

Last updated by the study team

2017-04-13

Who can join

Age: 14 and older, up to 45. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Ages 14 to 45, inclusive
• Episodes of prolonged penile erection in the absence of sexual interest or desire, with an average frequency of at least twice weekly, when averaged over the previous four weeks
• Able to provide informed consent or assent

You may not qualify if…

• Use of chronic nitrates or recreational use of nitrate containing products
• Use of a PDE5 (phosphodiesterase type 5)inhibitor within the previous two weeks
• Alcohol use exceeding two standard drinks daily
• Hypersensitivity to sildenafil
• Estimated glomerular filtration rate <50ml/min
• Known cirrhosis
• Retinitis pigmentosa
• Necessary use of a P450 3A4 inhibitor (a drug which can increase plasma levels of sildenafil when taken together)

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.